Opendoor drops 51% after InvestingPro flagged overvaluation signal
Source link
Related Posts
US FDA declines to approve AbbVie’s wrinkle treatment due to manufacturing concerns (April 23)
US FDA declines to approve AbbVie’s wrinkle treatment due to manufacturing concerns (April 23) Source link
Caliway presents preclinical data on CBL-514 at obesity congress
Caliway presents preclinical data on CBL-514 at obesity congress Source link
Goldman Sachs initiates Prelude Therapeutics stock coverage as Early-Stage Biotech
Goldman Sachs initiates Prelude Therapeutics stock coverage as Early-Stage Biotech Source link